Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
In the third episode of BioStock's Market Signal, host Cecilia Hallström shines a spotlight on the international connections and capital strategies currently shaping the Nordic life science scene. In conversations with key players in the industry, we highlight global billion-dollar deals, US listing plans and the current funding climate.
We begin with a highly topical interview with heavyweight investor Erik Selin and Li-Ming Gan, CEO of Ribocure.Together they discuss the company's recently secured global agreements and how the unique collaboration between Gothenburg and Hong Kong creates new conditions for attracting international capital.
We then take stock of the financial situation when Pieter van der Meijden from DNB Carnegie visits the studio.We summarise the first half of 2026, analyse the Nordic financing climate and discuss what is needed for local life science companies to compete in the global arena.
We conclude with a focus on Vicore Pharma, which recently applied for a parallel listing on US Nasdaq.CEO Ahmed Mousa talks about the US strategy, how the company will attract US institutional investors and the path forward for the upcoming phase IIb results in idiopathic pulmonary fibrosis.